Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)

Bibliographic Details
Main Authors:	McClanahan, F, Michallet, M, Milligan, D, Sutton, L, Brand, R, Richards, S, Van Biezen, A, Sobh, M, Gratwohl, A, Herr, W, Dearden, C, Hallek, M, Stilgenbauer, S, De Witte, T, Niederwieser, D, Leporrier, M, Dreger, P
Format:	Journal article
Published:	2010

Similar Items

Autologous haematopoietic stem cell transplantation in CLL: first results of an EBMT randomized trial comparing autotransplant versus wait and watch
by: Michallet, M, et al.
Published: (2010)

Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch
by: Michallet, M, et al.
Published: (2009)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT AND WATCH
by: Michallet, M, et al.
Published: (2010)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01)

Current strategies for the diagnosis and management of chronic lymphocytic leukemia (CLL), with a focus on poor-risk CLL: A review
by: Fabienne Mc Clanahan, et al.
Published: (2011-05-01)

Current strategies for the diagnosis and management of chronic lymphocytic leukemia (CLL), with a focus on poor-risk CLL: A review
by: Fabienne Mc Clanahan, et al.
Published: (2011-06-01)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

Quality of life in the LRF CLL4 trial.
by: Else, M, et al.
Published: (2005)

Current Treatment Options in CLL
by: Moritz Bewarder, et al.
Published: (2021-05-01)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
by: Nadine Kutsch, et al.
Published: (2020-02-01)

Experiences in the design and implementation of phase II trials in CLL
by: Cohen Dena R, et al.
Published: (2011-12-01)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

From Biology to Therapy: The CLL Success Story
by: Deyan Y. Yosifov, et al.
Published: (2019-04-01)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
by: Binet, J, et al.
Published: (1998)

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
by: Alexander Egle, et al.
Published: (2019-04-01)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
by: Florian Simon, et al.
Published: (2023-08-01)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
by: Petra Langerbeins, et al.
Published: (2023-08-01)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

PB1952: CLL IN AYA
by: Shehab Mohamed, et al.
Published: (2023-08-01)

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
by: William K Decker, et al.
Published: (2012-01-01)

Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
by: Gonzalo Blanco, et al.
Published: (2018-06-01)

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
by: Guièze, R, et al.
Published: (2015)

FAVORABLE OUTCOME IN CLL PATIENTS NOT TREATED DESPITE PRESENTING IWCLL CRITERIA: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN CLL GROUP
by: F.M. Marques, et al.
Published: (2020-11-01)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
by: Yucai Wang, et al.
Published: (2021-08-01)

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.
by: Michallet, M, et al.
Published: (2011)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
by: Moritz Fürstenau, et al.
Published: (2019-10-01)

NF-kB and the CLL microenvironment
by: Alice O’Donnell, et al.
Published: (2023-03-01)

Glabellar and auricular leukemia cutis in CLL
by: Bradley Steinman, et al.
Published: (2022-11-01)